This funding program — an Edmond J. Safra Core Program for PD Research — will support development of Parkinson’s disease (PD) therapeutics with potential for fundamentally altering disease course or significantly improving non-motor or motor symptoms.
Please note, this round, we are funding only pre-clinical studies. We will review applications for clinical studies in future rounds of this program.
The Therapeutic Pipeline Program funds novel approaches and interventions as well as repurposed or repositioned therapies approved or clinically safe from other disease indications. Pharmacological and non-pharmacological therapies are encouraged to apply.
- Assay development, early screening campaigns, hit-to-lead and lead optimization
- Pharmacokinetics, pharmacodynamics and safety
Studies may request access to MJFF-sponsored biospecimen and cell line collections.
Researchers from public and private institutions are encouraged to apply and to collaborate.
We will host a webinar on August 24, 2021, at 12 p.m. ET to clarify and explain the goals of our funding opportunities and answer applicant questions. The webinar will be available to view on-demand after the live airdate. Register today.
Email email@example.com with questions.